+91 97731 34699 [email protected]

Chemical Structure

PLGA
CAS Number26780-50-7
Systematic Name:1, 4-Dioxane-2, 5-dione-1-DL-3, 6-dimethyl-1, 4-dioxane-2, 5-dione copolymer, Glycolide – lactide copolymer, Glycolide-DL-lactide copolymer, Glycolide-DL-lactide polymer, Lactide – glycolide copolymer, Lactomer, Poly(dl-lactide-co-glycolide), Poly(glycolide – lactide), Poly(glycolide-co-lactide), Polyglactin
Molecular Formula:((C3H4O2)m x (C2H2O2)n
EPA Registry Name:Polylactic acid-polyglycolic acid copolymer
Former CAS Number(s)107760-14-5, 119652-89-0, 1255770-56-9, 130953-65-0, 31213-75-9, 339986-68-4
Substance Type:PLGA 50 50 | Inherent Viscosity : 0.15 – 0.30 | Acid terminated  | Lactide : Glycolide 50:50 | Mw 5-20 kDa
Biodegradable Polymer, Excipient, Non-Active pharmaceutical ingredient, Nanoparticles.
Synonym: PLGA, Poly(D,L-lactide-co-glycolide) acid terminated, Poly(DL-lactide-co-glycolide), acid terminated

Qualitative Analysis

AppearanceWhite to tan coloured solid powder
Inherent viscosity (IV)0.15 – 0.30 dL/g, in chloroform(25 °C)
Lactide by 1H NMR50% ( ± 2%)
Glycolide by 1H NMR50% ( ± 2%)

Quantitative Analysis

Assay≥ 98 %
Residual monomer≤ 0.2 %
Residual solventComplies
Heavy metalComplies

Application

Poly(D, L-lactide-co-glycolide)- DLG 50-2A (PLGA) has been one of the most attractive Biodegradable and biocompatible polymers used to fabricate devices for diagnostics and other applications of clinical and basic science research, including vaccine, cancer, cardiovascular disease, and tissue engineering. In addition, PLGA and its copolymers are Essential in designing nanoparticles with desired characteristics such as biocompatibility, biodegradation, particle size, surface properties, drug release, and targetability and exhibit a wide range of erosion times. PLGA has been approved by the US FDA for use in drug delivery complex formulation and biodegradable orthopedic Medical implants.

Reference :

  1. Sahoo S.K., Labhasetwar V.: Nanotech approaches to drug delivery and imaging. Drug Discov Today. 2003, 8(24), 1112-1120.
  2. Wickline S. A., Neubauer A. M., Winter P., Caruthers S., Lanza G.: Applications of nanotechnology to atherosclerosis, thrombosis, and vascular biology, Arteriosclerosis, Thrombosis, and Vascular Biology. 2006, 26(3), 435- 441.
  3. Pinto Reis C., Neufeld R. J., Ribeiro A. J., Veiga F.: Nanoencapsulation I. Methods for preparation of drug-loaded polymeric Nanoparticles, Nanomedicine. 2006, 2, 8-21.
  4. Hawker C. J. Wooley K. L.: Review: The convergence of synthetic organic and polymer chemistries, Science. 2005; 309(5738):1200–1205.
  5. Stevanoviae M., Savile J., Jordoviae B., Uskokoviae D.: Fabrication, in vitro degradation and the release behaviors of poly (DL-lactide-co-glycolide) nanospheres containing ascorbic acid, Colloids, and Surfaces B Biointerfaces. 2007, 59(2), 215-223.
  6. Verger M. L., Fluckiger L., Kim Y. I., Hoffman M., Maincent P.: Preparation and characterization of nanoparticles containing an antihypertensive agent, Eur J Pharm Biopharm. 1998, 46(2), 137-43.
  7. Astete C. E., Sabliov C. M.: Synthesis and characterization of PLGA Nanoparticles, J of Biomaterials Sci. 2006, 17(3), 247–289.

 

Inquire Now

  • This field is for validation purposes and should be left unchanged.